Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) | Journal of Clinical Oncology
PURPOSEAlkylating agents (ALKY) are the main chemotherapies used for advanced neuroendocrine tumors (NETs). O6-Methylguanine-DNA methyltransferase (MGMT) status, as proficient (p) or deficient (d), may predict the response to ALKY.PATIENTS AND METHODSMGMT-…MGMT is relevant to predict the response to alkylating agents such as temozolomide in neuroendocrine tumors
